Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile - commonly known as C. diff - are a serious and persistent problem for patients and ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx previously announced that it had received positive regulatory guidance from the ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...